Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Travere Therapeutics Inc shares valued at $4,888 were sold by Cline Christopher R. on Sep 04 ’24. At $9.51 per share, Cline Christopher R. sold 514 shares. The insider’s holdings dropped to 70,335 shares worth approximately $0.7 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Cline Christopher R. sold 54 shares, netting a total of over 364 in proceeds. Following the sale of shares at $6.74 each, the insider now holds 70,849 shares.
Before that, Dube Eric M had sold 19,122 shares from its account. In a trade valued at $166,435, the CHIEF EXECUTIVE OFFICER traded Travere Therapeutics Inc shares for $8.70 each. Upon closing the transaction, the insider’s holdings decreased to 19,122 shares, worth approximately $3.48 million.
As published in a research note from Guggenheim on March 27, 2024, Travere Therapeutics Inc [TVTX] has been rated down from a Buy to a Neutral. Analysts at Citigroup upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in early December. As of November 20, 2023, Citigroup has initiated its “Neutral” rating for TVTX. Earlier on September 22, 2023, Wells Fargo downgraded its rating. Their new recommendation was “an Equal weight” for TVTX stock which previously was a “an Overweight”.
Analyzing TVTX Stock Performance
During the last five days, there has been a surge of approximately 9.97%. Over the course of the year, Travere Therapeutics Inc shares have jumped approximately 10.46%. Shares of the company reached a 52-week high of $10.72 on 07/29/24 and a 52-week low of $5.12 on 04/25/24. A 50-day SMA is recorded $9.13, while a 200-day SMA reached $7.97. Nevertheless, trading volume fell to 1.12 million shares from 1.95 million shares the previous day.
Support And Resistance Levels for Travere Therapeutics Inc (TVTX)
According to the 24-hour chart, there is a support level at 9.46, which, if violated, would cause prices to drop to 8.99. In the upper region, resistance lies at 10.38. The next price resistance is at 10.83. RSI (Relative Strength Index) is 64.76 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.69, which suggests the price will decrease in the coming days. Percent R is at 22.43%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.